From High Throughput Screening to Scalable Solutions for Lentiviral Purification 

Lentiviral vectors are being increasingly used as tools for stable integration of large gene inserts into the genomes of both dividing and non-dividing cells. Currently, lentiviral-based therapies are primarily used ex-vivo, such as CAR-T cell therapy; however, recent animal studies have also successfully demonstrated their use for in-vivo applications. To enable more widespread use, as well as development of in-vivo therapies in humans, better downstream processes for lentiviral purification are needed. 

In this work, the results of lentiviral downstream optimisation on CIM^® QA Monolithic Well Plate with the use of design of experiment (DoE) is presented. By using DoE, infectious lentiviral recovery was increased to 70%, representing a threefold improvement over the initial results. Salt concentration in the loading sample was identified as the most critical factor for achieving high infectious recovery of lentivirus from the CIMmultus^® QA chromatography column